- Home
- SISI vs INAB Comparison
SISI vs INAB Comparison
Compare SISI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- INAB
- Stock Information
- Founded
- SISI 1997
- INAB 2016
- Country
- SISI China
- INAB United States
- Employees
- SISI N/A
- INAB N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- INAB Health Care
- Exchange
- SISI Nasdaq
- INAB Nasdaq
- Market Cap
- SISI 6.5M
- INAB 7.5M
- IPO Year
- SISI 2016
- INAB 2021
- Fundamental
- Price
- SISI $5.33
- INAB $2.29
- Analyst Decision
- SISI
- INAB Strong Buy
- Analyst Count
- SISI 0
- INAB 2
- Target Price
- SISI N/A
- INAB $108.00
- AVG Volume (30 Days)
- SISI 279.7K
- INAB 114.5K
- Earning Date
- SISI 09-29-2025
- INAB 08-07-2025
- Dividend Yield
- SISI N/A
- INAB N/A
- EPS Growth
- SISI N/A
- INAB N/A
- EPS
- SISI N/A
- INAB N/A
- Revenue
- SISI $9,601,324.00
- INAB N/A
- Revenue This Year
- SISI N/A
- INAB N/A
- Revenue Next Year
- SISI N/A
- INAB N/A
- P/E Ratio
- SISI N/A
- INAB N/A
- Revenue Growth
- SISI 1133.26
- INAB N/A
- 52 Week Low
- SISI $4.71
- INAB $1.98
- 52 Week High
- SISI $852.00
- INAB $21.21
- Technical
- Relative Strength Index (RSI)
- SISI 30.48
- INAB 49.17
- Support Level
- SISI $6.10
- INAB $2.01
- Resistance Level
- SISI $7.15
- INAB $2.38
- Average True Range (ATR)
- SISI 1.21
- INAB 0.14
- MACD
- SISI 0.06
- INAB 0.04
- Stochastic Oscillator
- SISI 0.34
- INAB 52.54
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.